Enliven Therapeutics
ELVN
210 hedge funds and large institutions have $4.06B invested in Enliven Therapeutics in 2026 Q2 according to their latest regulatory filings, with 63 funds opening new positions, 87 increasing their positions, 47 reducing their positions, and 18 closing their positions.
250% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 18
85% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 47
66% more capital invested
Capital invested by funds: $2.44B → $4.06B (+$1.61B)
34% more call options, than puts
Call options by funds: $9.35M | Put options by funds: $6.97M
30% more funds holding in top 10
Funds holding in top 10: 10 → 13 (+3)
26.56% more ownership
Funds ownership: 105% → 131.56% (+27%)
24% more funds holding
Funds holding: 170 → 210 (+40)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$136M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$119M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$57.9M |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$49.2M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$50.9M |
| 2 |
O
OrbiMed
New York
|
-$50.2M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$35.3M |
| 4 |
JHC
Jones Hill Capital
New York
|
-$23.1M |
| 5 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$15.7M |
ELVN Hedge Fund Activity: Q2 2026 in Review
210 institutional investors reported a position in Enliven Therapeutics (ELVN) for Q2 2026, worth a combined $4.06B — up 66% from $2.44B a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new ELVN positions and 18 closed out — a net gain of 45 holders — while 87 added to existing stakes and 47 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $136M. The largest seller was VR Adviser, cutting an estimated $50.9M.
- 210 institutional investors held Enliven Therapeutics (ELVN) as of Q2 2026, up from 170 in Q1 2026.
- Funds reported $4.06B of Enliven Therapeutics stock for Q2 2026, up 66% quarter-over-quarter.
- 63 funds opened new Enliven Therapeutics positions in Q2 2026 and 18 closed out, a net change of +45 holders.
- The largest Enliven Therapeutics buyer in Q2 2026 was Fidelity Investments, an estimated $136M added.
- The largest Enliven Therapeutics seller in Q2 2026 was VR Adviser, an estimated $50.9M sold.
Based on aggregated 13F filings for Q2 2026.